- Previous Close
0.0760 - Open
0.0760 - Bid 0.0760 x --
- Ask 0.0750 x --
- Day's Range
0.0760 - 0.0760 - 52 Week Range
0.0750 - 0.2850 - Volume
605 - Avg. Volume
3,470 - Market Cap (intraday)
4.049M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Feb 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of renal fibrosis. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
www.vectusbiosystems.com.auRecent News: VBS.AX
View MorePerformance Overview: VBS.AX
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VBS.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VBS.AX
View MoreValuation Measures
Market Cap
4.05M
Enterprise Value
3.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-255.56%
Return on Assets (ttm)
-61.34%
Return on Equity (ttm)
-163.00%
Revenue (ttm)
884.21k
Net Income Avi to Common (ttm)
-2.26M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
809.89k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-739.01k